Butyric and Gluconic Acid Postbiotic Composition for Intestinal Barrier Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intestinal disorders associated with low-grade chronic inflammation and intestinal barrier dysfunctions, such as IBS and IBD, face limitations including dose requirements, viability, colonization, and safety concerns, particularly in vulnerable populations.
Innovation Solution
A composition combining butyric acid or its salts with gluconic acid in specific weight ratios, ranging from 4:1 to 60:1, to enhance anti-inflammatory activity in the intestine, thereby addressing the limitations of conventional probiotic, prebiotic, and synbiotic products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotics are used to treat intestinal disorders, then beneficial functions are provided through metabolite production, but limitations arise in dose requirements, viability, colonization ability, and safety in vulnerable populations
Solution Approach 1:
The patent extracts the beneficial therapeutic function from probiotic microorganisms by isolating their metabolites (postbiotics) and using these purified compounds directly. This eliminates the safety risks associated with live microorganisms in vulnerable populations while maintaining the therapeutic benefits of probiotic metabolite production
Solution Approach 2:
The patent uses postbiotic metabolites as an intermediary substance that mediates the beneficial effects of probiotics without requiring the presence of live microorganisms. These metabolites serve as a safe alternative that can be administered to vulnerable populations without the colonization and viability issues of live probiotics
2Reliability
If prebiotic fibres are used to promote intestinal microbiota growth, then dysbiosis is helped and inflammation is controlled, but large amounts (grams) must be used and abdominal pain may be accentuated
Solution Approach 1:
The patent changes the parameter of substance concentration by using highly concentrated postbiotic metabolite preparations. This allows therapeutic efficacy to be achieved with much smaller doses (milligrams rather than grams) compared to prebiotic fibres, eliminating the need for large dosage amounts and associated gastrointestinal discomfort
3Reliability
If prebiotic fibres are used in large amounts to achieve prebiotic effect, then beneficial effects are obtained, but they can become a nutrient substrate for harmful bacterial species
Solution Approach 1:
The patent extracts only the beneficial postbiotic metabolites from the microbial fermentation process, separating them from the prebiotic substrate. This eliminates the problem of prebiotic fibres serving as nutrients for harmful bacteria while retaining the therapeutic benefits of the metabolites produced
Solution Approach 2:
The patent converts the fermentation process, which can potentially produce harmful byproducts when large amounts of prebiotic substrate are present, into a controlled production system for beneficial postbiotic metabolites. The harmful aspect of substrate availability is eliminated while the beneficial metabolite production is maximized
Data Source
AI summary
Disclosed are pharmaceutical or nutraceutical compositions comprising butyric acid or a salt thereof and gluconic acid, which are useful in the treatment of disorders and syndromes associated with intestinal barrier dysfunctions and dysbiosis.